Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to demonstrate the bioequivalence between the BRV tablet and BRV as dry syrup after a single oral dose in healthy Japanese male study participants.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05315947
Study type Interventional
Source UCB Pharma
Contact
Status Completed
Phase Phase 1
Start date April 4, 2022
Completion date May 13, 2022

See also
  Status Clinical Trial Phase
Terminated NCT04136444 - A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function Phase 1
Terminated NCT04126343 - A Study to Test the Cardiac Effects of Padsevonil in Healthy Study Participants Phase 1
Completed NCT05845645 - A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharamacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B Phase 1
Completed NCT04802746 - A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild Asthma Phase 1
Completed NCT04782388 - Study to Assess the Safety, Tolerability, And Pharmacokinetics of Staccato Alprazolam in Healthy Japanese, Chinese, and Caucasian Participants Phase 1
Recruiting NCT06312566 - A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study Participants Phase 1
Completed NCT05292131 - A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants Phase 1
Terminated NCT04444466 - A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants Phase 1
Completed NCT04705350 - A Study to Test Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants Phase 1
Terminated NCT04255862 - A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants Phase 1
Completed NCT04867642 - A Study to Test the Safety, Tolerability, and Blood Levels of UCB0022 in Healthy Participants and Participants With Parkinson's Disease Phase 1
Completed NCT04828343 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rozanolixizumab Administered Subcutaneously Via Manual Push Versus Syringe Driver to Healthy Participants Phase 1